Aducanumab
1 paper3 findings
- 1 lab in 1 country
- 3 on aging of 12 trials, 6 with no results posted
- 11 of 12 trials sponsored by its developers
- Animals1
Outcomes
3Healthspan
no changein mice1
1 study
Healthspan
no changein mice1
Aducanumab has no effect on healthspan in mice.
“Reduction of Aβ plaques did not correspond to significant improvements in performance on cognitive tasks or healthspan measures.”
Animalsin 5XFAD mice
Differential effects of sex on amyloid lowering by Aducanumab and IgG in 5xFAD mice
AAIC 2025 abstract26 Dec 2025
Cognitive function
no changein mice1
1 study
Cognitive function
no changein mice1
Aducanumab has no effect on cognitive function in mice.
“Reduction of Aβ plaques did not correspond to significant improvements in performance on cognitive tasks or healthspan measures.”
Animalsin 5XFAD mice
Differential effects of sex on amyloid lowering by Aducanumab and IgG in 5xFAD mice
AAIC 2025 abstract26 Dec 2025
Amyloid-beta
downin mice1
1 study
Amyloid-beta
downin mice1
Aducanumab decreases amyloid-beta in mice.
“Both ch Aducanumab and IgG were effective in attenuating plasma and brain Aβ”
Animalsin 5XFAD mice
Differential effects of sex on amyloid lowering by Aducanumab and IgG in 5xFAD mice
AAIC 2025 abstract26 Dec 2025
Trials
3 on aging of 12On aging
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Phase 3Terminated
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Phase 3Terminated
Phase 3Terminated
Approved
7 Jun 2021
Every condition in trials
Phase 3Terminated9 trials
Phase 2Terminated2 trials
Stopped
NCT02477800TerminatedAlzheimer's disease
Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed
NCT02484547TerminatedAlzheimer's disease
Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed
NCT04241068TerminatedAlzheimer's disease
Sponsor's Decision
NCT05310071TerminatedAlzheimer's disease
Sponsor's Decision
NCT03639987TerminatedCognitive dysfunction
Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.
Development
- Companies
- BiogenPhase 3Alzheimer's disease